2021
Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015
Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Re V, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Network Open 2021, 4: e2037512. PMID: 33595662, PMCID: PMC7890526, DOI: 10.1001/jamanetworkopen.2020.37512.Peer-Reviewed Original ResearchConceptsHCC incidence ratesHigher HCC riskHepatitis C virusHepatitis B virusModern cART eraCD4 cell countIncidence rateCART eraHCC riskHepatocellular carcinomaCohort studyTriple infectionNorth American AIDS Cohort CollaborationCell countAvailable CD4 cell countHigher HIV RNA levelsLow CD4 cell countsCombination antiretroviral therapy eraDiagnosis of HCCAnti-HCV seropositivityAntiretroviral therapy eraHBV-HCV coinfectionRecent HIV RNAHIV RNA levelsHBV e antigen
2019
HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status
Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Re V. HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. Journal Of The National Cancer Institute 2019, 112: 747-755. PMID: 31687755, PMCID: PMC7357318, DOI: 10.1093/jnci/djz214.Peer-Reviewed Original ResearchConceptsRisk of HCCHigher HIV RNAHCC risk factorsHIV RNAHIV viremiaHepatocellular carcinomaBaseline cirrhosisCirrhosis statusCohort studyRisk factorsCell percentageVeterans Aging Cohort StudyDevelopment of HCCCurrent HIV RNADetectable HIV viremiaHepatitis C coinfectionAging Cohort StudyDiagnosis of cirrhosisLonger durationDetectable HIVLow CD4C coinfectionCurrent CD4Hazard ratioCancer RegistryOpioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment
McGinnis KA, Fiellin DA, Skanderson M, Hser YI, Lucas GM, Justice AC, Tate JP, Group F. Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment. Drug And Alcohol Dependence 2019, 204: 107511. PMID: 31546119, PMCID: PMC6993986, DOI: 10.1016/j.drugalcdep.2019.06.014.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentHIV-1 RNADetectable HIV-1 RNAUninfected patientsAgonist treatmentVeterans Aging Cohort StudyResponsiveness of CD4Substance use disorder treatmentHealth effectsUrine toxicology resultsUrine toxicology testsAging Cohort StudyElectronic health record dataUse disorder treatmentHealth record dataPhysical health effectsRace/ethnicityOAT initiationCohort studyOpioid useBiomarker changesToxicology resultsNegative groupUninfected individualsDisorder treatmentImproved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals
Tate JP, Sterne JAC, Justice AC. Improved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals. AIDS 2019, Publish Ahead of Print: &na;. PMID: 30649058, PMCID: PMC6749990, DOI: 10.1097/qad.0000000000002140.Peer-Reviewed Original ResearchConceptsWhite blood countC-statisticBlood countVeterans Aging Cohort Study (VACS) IndexAntiretroviral Therapy Cohort CollaborationDiscrimination of mortalityVACS Index 2.0Antiretroviral therapy initiationCD4 cell countHIV-positive populationHarrell's C-statisticHIV-1 RNAHIV-positive individualsKaplan-Meier plotsCohort CollaborationNadir CD4VAC patientsAntiretroviral therapyCause mortalityCD8 ratioTherapy initiationViral suppressionGeneral healthExcess mortalityLaboratory valuesEmulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals
Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández‐Díaz S, Meyer L, Seng R, Drozd DR, Seage G, Bonnet F, Le Marec F, Moore RD, Reiss P, Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals. Statistics In Medicine 2019, 38: 2428-2446. PMID: 30883859, PMCID: PMC6499640, DOI: 10.1002/sim.8120.Peer-Reviewed Original ResearchConceptsHIV-positive individualsCopies/First-line treatment regimenAIDS Research NetworkAIDS-free survivalCells/Integrated Clinical SystemsHIV-CAUSAL CollaborationOutcomes of interestRisk difference estimatesDirect effectAntiretroviral therapyHIV RNACD4 thresholdTreatment regimenNew regimenTreatment strategiesHIV researchTarget trialsRegimenTherapyResearch NetworkTrialsSurvivalClinical systems
2018
Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study
Hawkins KL, Gordon KS, Levin MJ, Weinberg A, Battaglia C, Rodriguez-Barradas MC, Brown ST, Rimland D, Justice A, Tate J, Erlandson KM. Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 527-533. PMID: 30179984, PMCID: PMC6203599, DOI: 10.1097/qai.0000000000001846.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyHerpes zoster ratesHerpes zosterAging Cohort StudyUninfected adultsUninfected veteransVaccine receiptZoster vaccineCohort studyHIV serostatusStudy periodCART-treated individualsCombination antiretroviral therapyHIV-1 RNAHigh rateLow CD4Vaccine guidelinesZoster vaccinationAntiretroviral therapyVaccine ratesStudy endPharmacy dataEffective vaccinePLWHZoster
2017
Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada
Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, Althoff KN, Achenbach CJ, Hessol NA, Modur SP, D'Souza G, Bosch RJ, Grover S, Horberg MA, Kitahata MM, Mayor AM, Novak RM, Rabkin CS, Sterling TR, Goedert JJ, Justice AC, Engels EA, Moore RD, Silverberg MJ. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 382-390. PMID: 28394855, PMCID: PMC5490794, DOI: 10.1097/qai.0000000000001394.Peer-Reviewed Original ResearchConceptsT-cell countsKS riskCD4 countKaposi's sarcomaART useHIV-1 RNA viral loadNorth American AIDS Cohort CollaborationTime-updated Cox regressionCD4 T-cell countKaposi's sarcoma riskAntiretroviral therapy useRNA viral loadRecent CD4 countViral load measuresAssociation of CD4Cohort CollaborationKS etiologyRecent VLVL measuresAntiretroviral therapyHIV diagnosisIndependent predictorsTherapy useViral loadCox regression
2016
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries
Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 72: 214-221. PMID: 26895294, PMCID: PMC4866894, DOI: 10.1097/qai.0000000000000956.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsAntiretroviral therapyCell countAIDS-defining illnessAntiretroviral-naive individualsAIDS Research NetworkMortality hazard ratioHIV-positive personsIntegrated Clinical SystemsHIV-CAUSAL CollaborationVirologic outcomesHIV RNAVirologic failureHazard ratioClinical outcomesProspective studyRisk ratioHigh-income countriesEligible individualsMonths strategyMonthsIllnessDeathTherapy
2015
Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy
Viswanathan S, Justice AC, Alexander GC, Brown TT, Gandhi NR, McNicholl IR, Rimland D, Rodriguez-Barradas MC, Jacobson LP. Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 493-498. PMID: 25886923, PMCID: PMC4482798, DOI: 10.1097/qai.0000000000000643.Peer-Reviewed Original ResearchConceptsHIV RNA suppressionOdds of suppressionActive antiretroviral therapyRNA suppressionHAART regimenAntiretroviral therapyVeterans Aging Cohort Study Virtual CohortHighly Active Antiretroviral TherapyFirst HAART regimenProtease inhibitor usersRepeated-measures logistic regressionVeterans' Affairs pharmacyViral load suppressionHAART usersNew HAARTRegimen typeInhibitor usersHIV infectionNonnucleoside reverseLow adherenceAdherence levelsPerfect adherenceVirtual cohortLogistic regressionDuration of timeThirty-Day Postoperative Mortality Among Individuals With HIV Infection Receiving Antiretroviral Therapy and Procedure-Matched, Uninfected Comparators
King JT, Perkal MF, Rosenthal RA, Gordon AJ, Crystal S, Rodriguez-Barradas MC, Butt AA, Gibert CL, Rimland D, Simberkoff MS, Justice AC. Thirty-Day Postoperative Mortality Among Individuals With HIV Infection Receiving Antiretroviral Therapy and Procedure-Matched, Uninfected Comparators. JAMA Surgery 2015, 150: 343-351. PMID: 25714794, PMCID: PMC5015449, DOI: 10.1001/jamasurg.2014.2257.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionCD4 cell countImmunodeficiency virus infectionAntiretroviral therapyPostoperative mortalityHIV infectionHIV-1 RNAIncidence rate ratiosUninfected patientsVirus infectionCell countUninfected comparatorsSurgical outcomesSurgical proceduresCD4 cell count strataCharlson Comorbidity Index scoreCommon inpatient surgical proceduresHIV-1 RNA levelsThirty-day postoperative mortalityUndetectable HIV-1 RNAVeterans Health Administration healthcare systemElectronic medical record dataCombination antiretroviral therapyComorbidity Index scoreCoronary artery bypass
2014
Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings
Butt AA, Yan P, Shaikh OS, Freiberg MS, Re V, Justice AC, Sherman KE, Team T. Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings. Journal Of Viral Hepatitis 2014, 22: 691-700. PMID: 25524834, PMCID: PMC5020421, DOI: 10.1111/jvh.12375.Peer-Reviewed Original ResearchConceptsSustained virologic responsePEG/RBVHaematologic toxicityActual clinical settingsSVR ratesVirologic responseClinical settingHaematologic adverse eventsHCV Infected VeteransInterferon/ribavirinHCV genotype 1HCV RNA valuesPivotal clinical trialsHepatitis C virusBaseline cirrhosisHIV coinfectionPrimary endpointTreatment-naïveAdverse eventsC virusClinical trialsGenotype 1Genotype 1aSevere toxicityBoceprevirHepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals Of Internal Medicine 2014, 160: 369-79. PMID: 24723077, PMCID: PMC4254786, DOI: 10.7326/m13-1829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAscitesBacterial InfectionsCarcinoma, HepatocellularCoinfectionEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatitis C, ChronicHIVHIV InfectionsHumansIncidenceLiver NeoplasmsMaleMedication AdherenceMiddle AgedPeritonitisRetrospective StudiesRNA, ViralTreatment OutcomeViral LoadConceptsCo-infected patientsHepatitis C virusHepatic decompensationAntiretroviral-treated patientsCohort studyNonblack raceC virusHepatitis C virus-monoinfected patientsChronic hepatitis C virusHigh rateAntiretroviral therapy eraDetectable HCV RNAIncident hepatic decompensationBaseline hemoglobin levelRetrospective cohort studySpontaneous bacterial peritonitisAdvanced hepatic fibrosisAdvanced liver fibrosisVeterans Health AdministrationDiagnosis of ascitesRate of decompensationTherapy eraHIV RNAVariceal hemorrhageHCV RNAHIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function.
So-Armah KA, Chang J, Alcorn C, Lo Re V, Baker JV, Tracy R, Butt AA, Agan BK, Rimland D, Gibert CL, Goetz MB, Oursler KK, Rodriguez-Barradas MC, Kuller LH, Brown ST, Stein JH, Skanderson M, Justice AC, Freiberg MS. HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. Current HIV Research 2014, 12: 50-9. PMID: 25034208, PMCID: PMC4495647, DOI: 10.2174/1570162x1201140716101512.Peer-Reviewed Original ResearchConceptsART initiationHIV infectionHIV infection levelsViral suppressionLongitudinal changesLDL cholesterolPositive HIV antibody testBiomarker measurementsAge-related chronic diseasesAntiretroviral therapy initiationEnd-organ diseaseFIB-4 scoreHIV antibody testWilcoxon signedrank testUninfected veteransVACS-VCFIB-4Therapy initiationHIV levelsHDL cholesterolSerum levelsTotal cholesterolPlatelet countMean ageChronic diseases
2013
Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals
Lucas G, Jing Y, Sulkowski M, Abraham A, Estrella M, Atta M, Fine D, Klein M, Silverberg M, Gill M, Moore R, Gebo K, Sterling T, Butt A, for the NA-ACCORD of the IeDEA, Kirk G, Benson C, Bosch R, Collier A, Boswell S, Grasso C, Mayer K, Hogg R, Harrigan R, Montaner J, Cescon A, Brooks J, Buchacz K, Gebo K, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Horberg M, Thorne J, Goedert J, Jacobson L, Klein M, Rourke S, Burchell A, Rachlis A, Rico P, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Patel P, Brooks J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Justice A, Dubrow R, Fiellin D, Sterling T, Haas D, Bebawy S, Turner M, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Webster E, Morton L, Simon B, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Hanna D, Rebeiro P, Wong C, Mendes A. Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. The Journal Of Infectious Diseases 2013, 208: 1240-1249. PMID: 23904290, PMCID: PMC3778973, DOI: 10.1093/infdis/jit373.Peer-Reviewed Original ResearchConceptsStage 3 CKDStage 5 CKDProgressive CKDAviremic subjectsHazard ratioGlomerular filtration rate decreaseChronic kidney disease riskHepatitis C virus replicationHCV seronegative subjectsHCV viremic subjectsAdjusted hazard ratioChronic kidney diseaseHepatitis C viremiaKidney disease riskConfidence intervalsC virus replicationAdvanced CKDAviremic individualsCKD incidenceHCV-viremicSeronegative subjectsC viremiaViremic subjectsKidney diseaseCKDMedical ICU Admission Diagnoses and Outcomes in Human Immunodeficiency Virus–Infected and Virus–Uninfected Veterans in the Combination Antiretroviral Era*
Akgün KM, Tate JP, Pisani M, Fried T, Butt AA, Gibert CL, Huang L, Rodriguez-Barradas MC, Rimland D, Justice AC, Crothers K. Medical ICU Admission Diagnoses and Outcomes in Human Immunodeficiency Virus–Infected and Virus–Uninfected Veterans in the Combination Antiretroviral Era*. Critical Care Medicine 2013, 41: 1458-1467. PMID: 23507717, PMCID: PMC4283206, DOI: 10.1097/ccm.0b013e31827caa46.Peer-Reviewed Original ResearchConceptsMedical ICU admissionVeterans Aging Cohort Study (VACS) IndexICU admissionAntiretroviral therapyRespiratory diagnosesMechanical ventilationVeterans Aging Cohort Study Index scoresUndetectable HIV-1 RNALogistic regressionStudy indicesVeterans Affairs Medical CenterCombination antiretroviral eraCritical care requirementsICU admission diagnosisMedical ICU careCombination antiretroviral therapyInfection/sepsisHIV-1 RNAHuman immunodeficiency virusMultivariable logistic regressionRoutine clinical biomarkersHigh mortality rateRevenue center codesAdmission diagnosisICU mortalityAn internationally generalizable risk index for mortality after one year of antiretroviral therapy
Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013, 27: 563-572. PMID: 23095314, PMCID: PMC4283204, DOI: 10.1097/qad.0b013e32835b8c7f.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAlanine TransaminaseAnti-HIV AgentsAspartate AminotransferasesBiomarkersCD4 Lymphocyte CountCohort StudiesEuropeFemaleHemoglobinsHepatitis CHIV InfectionsHumansMaleMiddle AgedMultiple Organ FailurePlatelet CountPredictive Value of TestsRisk AssessmentRNA, ViralUnited StatesConceptsHIV-1 RNAVeterans Aging Cohort StudyMultiorgan system injuryCD4 cell countAntiretroviral therapyVACS IndexSystem injuryCell countDetectable HIV-1 RNAART Cohort CollaborationOutcome of deathAging Cohort StudyHepatitis C statusMortality risk indexGood discriminationART initiationCohort CollaborationHCV coinfectionCohort studyHIV deathsHIV markersHIV infectionValidation cohortAlanine transaminaseExcess mortalityA Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care
Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, Scott Braithwaite R. A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care. AIDS And Behavior 2013, 17: 2293-2300. PMID: 23404097, PMCID: PMC3742414, DOI: 10.1007/s10461-013-0416-1.Peer-Reviewed Original ResearchConceptsViral load suppressionFeasibility outcomesPatient acceptabilityPatient comprehensionPlasma HIV RNADetectable viral loadViral load testsSingle-site studyEligible patientsHIV careHIV RNAART adherenceViral loadHIV transmissionOwn controlPatientsPatient workflowFinancial incentivesOutcomesCareDownstream costsIncentive sizeBiological outcomesAcceptabilityClinicPredictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection
Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ. Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 62: 149-163. PMID: 23187941, PMCID: PMC3619393, DOI: 10.1097/qai.0b013e31827df36c.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAlanine TransaminaseAnti-Retroviral AgentsAspartate AminotransferasesBiomarkersCD4 Lymphocyte CountCohort StudiesCreatinineFemaleHemoglobinsHepatitis CHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPlatelet CountPredictive Value of TestsRisk AssessmentRNA, ViralSex FactorsConceptsNet reclassification improvementVeterans Aging Cohort Study (VACS) IndexVeterans Affairs Healthcare SystemAntiretroviral therapyPatient subgroupsNorth American AIDS Cohort CollaborationHIV-1 RNA levelsStudy indicesObserved mortalityPrior ART exposureVACS Index scoreHIV-1 RNAImportant patient subgroupsRisk of mortalityHealthcare systemDiverse patient subgroupsCohort CollaborationHIV biomarkersVACS IndexHIV infectionOrgan injuryParametric survival modelsART exposureReclassification improvementC-statistic
2012
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.
Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, Gange SJ, Moore RD, Kitahata MM, Gebo KA, Martin J, Justice AC, Horberg MA, Hogg RS, Sterling TR, Cescon A, Klein MB, Thorne JE, Crane HM, Mugavero MJ, Napravnik S, Kirk GD, Jacobson LP, Brooks JT. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Annals Of Internal Medicine 2012, 157: 325-35. PMID: 22944874, PMCID: PMC3534765, DOI: 10.7326/0003-4819-157-5-201209040-00005.Peer-Reviewed Original ResearchConceptsCD4 cell countCD4 T-lymphocyte cell countMedian CD4 cell countT-lymphocyte cell countAntiretroviral therapy useHIV VLCell countNA-ACCORDHIV RNATherapy useViral loadU.S. National HIV/AIDS StrategyHealth outcomesNational HIV/AIDS StrategyCanadian HIV Trials NetworkHIV/AIDS StrategyActive antiretroviral therapyHIV outpatient clinicAnnual cross-sectional analysesHIV Cohort StudyProportion of participantsNational surveillance systemRelated health outcomesSimilar demographic characteristicsCross-sectional analysisImpact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA. Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clinical Infectious Diseases 2012, 54: 1364-1372. PMID: 22460971, PMCID: PMC3404691, DOI: 10.1093/cid/cis203.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDeveloped CountriesDrug Therapy, CombinationEuropeFemaleHIV InfectionsHIV SeropositivityHumansImmune Reconstitution Inflammatory SyndromeIncidenceMaleMiddle AgedMycobacterium tuberculosisPneumocystis cariniiPneumonia, PneumocystisRNA, ViralTuberculosisUnited StatesViral LoadConceptsImmune reconstitution inflammatory syndromeCD4 cell countCells/μL.HIV RNA levelsHazard ratioTuberculosis incidenceCART initiationCell countAntiretroviral therapyTime-varying CD4 cell countBaseline CD4 cell countAIDS-free individualsEffects of CARTLow tuberculosis incidenceMonths of ARTReconstitution inflammatory syndromeHIV-positive patientsRNA levelsHIV-positive individualsHuman immunodeficiency virusHIV-CAUSAL CollaborationInflammatory syndromeImmunodeficiency virusInverse probability weightingPositive individuals